February 13, 2024. Summary ToggleMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome ...
People also ask
What does Merrimack Pharmaceuticals do?
Where is Merrimack Pharmaceuticals headquarters?
May 10, 2024 · Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share ...
Apr 30, 2024 · Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval ...
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from ...
Get the latest Merrimack Pharmaceuticals, Inc. (MACK) stock news and headlines to help you in your trading and investing decisions.
May 10, 2024 · Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share ...
(Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 ...
Merrimack Pharmaceuticals plans to announce top-line results for their PDUFA trial of ONIVYDE - (NAPOLI 3) on February 13, 2024. Currently, this drug has a 88.7 ...
Stay up-to-date on Merrimack Pharmaceuticals, Inc. Common Stock (MACK) news with the latest updates, breaking headlines, news articles, and more from around ...
Press Releases. May 10, 2024. Summary ToggleMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating ...